TLDR
- Q1 adjusted earnings reached $0.75 per share, surpassing the analyst consensus of $0.72
- Quarterly revenue totaled $13.8 billion, driven by robust Eliquis performance
- Net income declined 9% annually to $2.7 billion; diluted earnings per share decreased 10%
- Company maintains 2026 outlook: adjusted EPS of $2.80–$3.00 and revenue of $59.5B–$62.5B
- Shares climbed approximately 0.5% in premarket activity, reaching about $26.33
Pfizer delivered a solid first-quarter performance to start 2026, pushing shares up roughly 0.5% in premarket sessions to $26.33.
The pharmaceutical company reported adjusted earnings of $0.75 per share, exceeding Wall Street’s $0.72 projection. Quarterly revenue totaled $13.8 billion.
Eliquis, the company’s anticoagulant medication and among its top-selling products, demonstrated continued strength. The medication remains a critical component of the revenue mix as established therapies maintain performance above projections.
Chief Financial Officer David Denton highlighted 22% operational revenue expansion from newly launched and acquired therapies. This growth trajectory represents a strategic priority for the company moving forward.
Net income showed some pressure, falling to $2.7 billion, representing a 9% decrease compared to the year-earlier period. Diluted earnings per share settled at $0.47, marking a 10% year-over-year reduction.
Annual Projections Remain Unchanged
Pfizer confirmed its 2026 financial outlook, keeping intact the guidance initially provided in December. The company continues to target adjusted earnings per share between $2.80 and $3.00, alongside full-year revenue ranging from $59.5 billion to $62.5 billion.
Wall Street consensus estimates stood at $2.96 per share and $61.4 billion in revenue, both falling within the company’s projected ranges.
The pharmaceutical giant also stated it will refrain from share repurchases throughout 2026. This stance remains firm across all scenarios for the fiscal year.
Chief Executive Albert Bourla expressed optimism about the quarter. “We’re off to a strong start in 2026,” he remarked, highlighting favorable Phase 3 clinical trial results and promising mid-stage data.
Bourla emphasized oncology and obesity therapeutics as two therapeutic areas where he sees Pfizer “positioned to lead.”
Looming Patent Expirations Remain a Focus
Approaching patent expirations represent one of Pfizer’s significant near-term headwinds. Important intellectual property protections on major revenue-generating drugs, including Eliquis, face expiration dates within the coming years.
The company has implemented strategic measures to address this challenge. Management has negotiated arrangements with generic drug makers to prolong exclusivity periods on select medications, including Vyndaqel.
Additionally, Pfizer has expanded its product portfolio through strategic acquisitions and internal development initiatives to strengthen its pipeline.
The research and development pipeline continues to progress across numerous therapeutic areas, with oncology and obesity programs receiving particular emphasis from executive leadership.
First-quarter revenue increased 5% year-over-year to $14.5 billion on a reported basis, exceeding market projections ahead of the earnings announcement.
The performance across both earnings and revenue metrics provided investors with stronger-than-anticipated quarterly results.
